Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Berghoff, Anna S ^a   Fuchs, Elisabeth ^a   Ricken, Gerda ^a,b   Mlecnik, Bernhard ^c,d,e   Bindea, Gabriela ^c,d,e   Spanberger, Thomas ^a   Hackl, Monika ^f   Widhalm, Georg ^a   Dieckmann, Karin ^a   Prayer, Daniela ^a   Bilocq, Amelie ^c,d,e   Heinzl, Harald ^a   Zielinski, Christoph ^a   Bartsch, Rupert ^a   Birner, Peter ^a   Galon, Jerome ^c,d,e   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f Austrian National Cancer Registry   (Austria)

Author keywords

Brain metastases; Immunoscore; Overall survival; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN RADIATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84954429886     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1057388     Document Type: Article

References (31)

1. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1, 960 patients in the RTOG database. Int J Radiat Oncol, Biol, Phys 2008; 70:510-4; PMID:17931798; http://dx. doi. org/10. 1016/j. ijrobp. 2007. 06. 074
2. BerghoffAS, RajkyO, WinklerF, Bartsch R, Furtner J, Hainfellner JA, GoodmanSL, WellerM, SchittenhelmJ, Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro-oncology 2013; 15:1664-72; PMID:24084410; http://dx. doi. org/10. 1093/neuonc/not112
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx. doi. org/10. 1016/j. cell. 2011. 02. 013
4. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx. doi. org/10. 1038/nrc3245
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, CamusM, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx. doi. org/10. 1126/science. 1129139
6. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol: Off J Am Soc Clin Oncol 2014;32:2959-66; PMID:25071121; http://dx. doi. org/10. 1200/JCO. 2013. 55. 0491
7. Loi S, SirtaineN, Piette F, Salgado R, VialeG, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol: Off J Am Soc Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx. doi. org/10. 1200/JCO. 2011. 41. 0902
8. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. New Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx. doi. org/10. 1056/NEJMoa051424
9. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx. doi. org/10. 1016/j. immuni. 2013. 07. 008
10. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT et al. HLA class I antigen processing machinery component expression and intratumoral TCell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 2008; 14:3372-9; PMID:18519766; http://dx. doi. org/10. 1158/1078-0432. CCR-07-4433
11. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007; 28:12-8; PMID:17129764; http://dx. doi. org/10. 1016/j. it. 2006. 11. 004
12. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-oncology 2014; 17(8):1064-75; PMID:25355681; http://dx. doi. org/10. 1093/neuonc/ nou307
13. Platten M, Ochs K, Lemke D, Opitz C, Wick W. Microenvironmental clues for glioma immunotherapy. Curr Neurol Neurosci Rep 2014; 14:440; PMID:24604058; http://dx. doi. org/10. 1007/s11910-014-0440-1
14. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx. doi. org/10. 1158/1078-0432. CCR-13-3271
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx. doi. org/10. 1056/NEJMoa1200690
16. Berghoff A, Inan C, Ricken G, Widhalm G, Dieckmann K, Birner P, Oberndorfer F, Dome F, Bartsch R, Zielinski C et al. Tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in non-small cell lung cancer brain metastases (BM) and matched primary tumors (PT). ESMO 2014; 1324P
17. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Holler C, Preusser M. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2015; 66:289-99; PMID:25314639; http://dx. doi. org/10. 1111/his. 12537
18. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-65; PMID:22456429; http://dx. doi. org/10. 1016/S1470-2045(12)70090-6
19. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G et al. Cancer classification using the Immunoscore: a worldwide task force. J Trans Med 2012; 10:205; PMID:23034130; http://dx. doi. org/10. 1186/1479-5876-10-205
20. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Trans Med 2012; 10:1; PMID:22214470; http://dx. doi. org/10. 1186/1479-5876-10-1
21. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol: Off J Am Soc Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx. doi. org/10. 1200/JCO. 2010. 30. 5425
22. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx. doi. org/10. 1002/path. 4287
23. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010; 107:11906-11; PMID:20547866; http://dx. doi. org/10. 1073/pnas. 1002569107
24. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995; 55:1902-10; PMID:7728757
25. Spanberger T, Berghoff AS, Dinhof C, Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wohrer A, Hackl M, Widhalm G et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1 a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metast 2013; 30:357-68; PMID:23076770; http://dx. doi. org/ 10. 1007/s10585-012-9542-9
26. Woehrer A. Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. Clin Neuropathol 2013; 32:269-85; PMID:23611589; http://dx. doi. org/ 10. 5414/NP300600
27. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009; 95:401-11; PMID:19562257; http://dx. doi. org/ 10. 1007/s11060-009-9938-9
28. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Holler C, Preusser M. Tumor infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2014; 66:289-99; PMID:25314639; http://dx. doi. org/10. 1111/his. 12537
29. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, Palmqvist R. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Modern Pathol:Off J U S Can Acad Pathol, Inc 2011; 24:671-82; PMID:21240258; http://dx. doi. org/10. 1038/ modpathol. 2010. 234
30. AltmanDG, LausenB, SauerbreiW, SchumacherM. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86:829-35; PMID:8182763; http://dx. doi. org/10. 1093/jnci/86. 11. 829
31. Holländer N, Sauerbrei W, Schumacher M. Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med 2004; 23:1701-13; PMID:15160403; http://dx. doi. org/ 10. 1002/sim. 1611